Physician profile
Misook Joo
NPI 1598011371
$4,937.18
in general payments reported to CMS, 2019-2025
23 companies · $1,180 in 2025
The $1,180 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $649 · 2022: $992 · 2023: $1,047 · 2024: $1,069 · 2025: $1,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,295.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,679.38 | 2021-2025 | |
| Novo Nordisk INC | $580.91 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $465.26 | 2022-2025 | |
| Glaxosmithkline, LLC. | $350.69 | 2021-2025 | Arexvy, Penmenvy, Shingrix |
| Amgen INC. | $258.43 | 2023-2025 | Evenity, Prolia, Krystexxa |
| Merck Sharp & Dohme LLC | $229.69 | 2021-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Sumitomo Pharma America, INC. | $217.26 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $199.98 | 2021-2022 | |
| Pfizer INC. | $192.82 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $165.30 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $81.08 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $70.43 | 2024-2025 | Zenpep |
| Astrazeneca Pharmaceuticals LP | $68.32 | 2025 | Farxiga |
| Gilead Sciences, INC. | $60.89 | 2021-2022 | |
| Amarin Pharma, INC. | $54.77 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $50.44 | 2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $43.73 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $43.10 | 2024 | Voquezna |
| Edwards Lifesciences Corporation | $28.39 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Azurity Pharmaceuticals, INC. | $27.71 | 2025 | Horizant |
| Dexcom, INC. | $24.19 | 2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $23.33 | 2025 | Zepbound, Mounjaro |
| Medtronic, INC. | $21.08 | 2025 | Venaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misook Joo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.